Regeneron, Sanofi announce Dupixent authorization in Japan
Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Merck plans to launch US subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...
Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset ...
Health on MSN3d
How To Stop Scratching With Atopic Dermatitis: 12 Effective Tips
Medically reviewed by Katlein Franca, MD Atopic dermatitis is a chronic (long-lasting) skin condition that causes dry, itchy ...